Skip to content

Risk Education and Assessment for Cancer Heredity

Bridging Geographic Barriers: Remote Cancer Genetic Counseling for Rural Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01346761
Acronym
REACH
Enrollment
1012
Registered
2011-05-03
Start date
2009-08-31
Completion date
2012-12-31
Last updated
2016-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Genetic Predisposition, Ovarian Cancer

Keywords

Genetic Counseling, Genetic Counseling Interventions, Genetic Testing, BRCA1 gene, BRCA2 gene, Risk Communication

Brief summary

Individuals living in geographically underserved areas encounter considerable barriers to access of quality cancer genetic services. Although in-person genetic counseling has generally been accepted as the standard of care, the use of telecommunications to deliver clinical genetic services may help reduce this disparity in access to such services. However, before the widespread adoption of telephone-delivered cancer genetic services occurs, it is critical to analyze the efficacy and safety of this mode of communication. This two-group randomized equivalency/non-inferiority trial will determine whether telephone-based cancer genetic counseling is an acceptable alternative to the traditional in-person mode among women who have a personal or family history of breast and/or ovarian cancer strong enough to warrant genetic counseling and testing. This study's findings will provide important information to cancer centers and cancer control policies about the safety, efficacy, and costs of delivering telephone-based clinical cancer genetic services for geographically challenged women at risk for having Breast Cancer susceptibility gene (BRCA) 1/2 mutations.

Detailed description

Following confirmation of eligibility and completion of baseline surveys, participants will be randomly assigned to one of the study arms by the project coordinator, using a computer-generated allocation algorithm on the basis of a randomization blocks method using four, six or eight participants in each block. In-person and telephone counseling will be delivered by the same board-certified genetic counselors using a guideline-concordant semi-structured protocol that will allow for personalization of counseling. Participants randomly assigned to telephone counseling will be mailed packets that include a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer genetic counseling with visual aids. At the time of their session, participants will review the brochure and genetic counselors will use visual aids to explain breast-ovarian cancer genetics. Women receiving in-person counseling will be given the same materials during their session at the community clinic. For women who elect to have testing, those who have telephone counseling will be sent a genetic test kit; those who have in-person counseling will have the option of giving a sample immediately at the clinic, or will be given a test kit with the same instructions as those in the telephone-counseling group. When BRCA test results become available, participants will be offered individual post-test counseling with the same genetic counselor who conducted the pretest session.

Interventions

Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.

Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
University of Utah
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 74 Years
Healthy volunteers
Yes

Inclusion criteria

* Utah resident * Meets National Comprehensive Cancer Network (NCCN) guidelines for hereditary breast/ovarian cancer syndrome (personal and/or family history of breast and/or ovarian cancer, or is a member of a family with a known positive BRCA1/BRCA2 mutation).

Exclusion criteria

* Has had genetic counseling and/or BRCA 1/2 testing * Physically or mentally unable to complete telephone surveys, telephone or in-person counseling or provide informed consent. * Unable to read and speak English fluently * Unable to travel to in-person genetic counseling session (17 in-person sites throughout Utah) * Male gender

Design outcomes

Primary

MeasureTime frameDescription
Determine the non-inferiority/equivalency of telephone genetic counseling to standard in-person genetic counseling6 &12-month follow-up1. Compare utilization of BRCA1/BRCA2 testing among telephone genetic counseling relative to in-person genetic counseling. 2. Determine the safety and efficacy of telephone genetic counseling relative to in-person genetic counseling by evaluating psychological and quality of life outcomes. 3. Compare communication-related and decision-making outcomes among telephone genetic counseling relative to in-person genetic counseling.

Secondary

MeasureTime frameDescription
Determine the feasibility of the intervention1 week pre-test, 1 week post-test, 6 & 12 month follow-ups1. Examine the intervention delivery and patient costs of telephone genetic counseling relative to in-person genetic counseling. 2. Examine mediators (sociodemographic, communication factors, health care access, clinical, & psychosocial factors) of genetic testing decisions, and affective and cognitive outcomes. 3. Compare decisions and perceptions about use of primary/secondary prevention strategies for hereditary breast/ovarian cancer.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026